Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry

Archive ouverte

Kada Mohammed, Samia | Dabakuyo Yonli, Tienhan, Sandrine | Desmoulins, Isabelle | Manguem Kamga, Ariane | Jankowski, Clémentine | Padeano, Marie-Martine | Loustalot, Catherine | Costaz, Hélène | Causeret, Sylvain | Peignaux, Karine | Rouffiac, Magali | Coutant, Charles | Arnould, Laurent | Ladoire, Sylvain

Edité par CCSD ; Springer Verlag -

International audience. Purpose: The prognosis of local invasive recurrence (LIR) after prior carcinoma in situ (CIS) of the breast has not been widely studied and existing data are conflicting, especially considering the specific prognosis of this entity, compared to de novo invasive breast cancer (de novo IBC) and with LIR after primary IBC.Methods: We designed a retrospective study using data from the specialized Côte d'Or Breast and Gynecological cancer registry, between 1998 and 2015, to compare outcomes between 3 matched groups of patients with localized IBC: patients with LIR following CIS (CIS-LIR), patients with de novo IBC (de novo IBC), and patients with LIR following a first IBC (IBC-LIR). Distant relapse-free (D-RFS), overall survival (OS), clinical, and treatment features between the 3 groups were studied.Results: Among 8186 women initially diagnosed with IBC during our study period, we retrieved and matched 49 CIS-LIR to 49 IBC, and 46 IBC-LIR patients. At diagnosis, IBC/LIR in the 3 groups were mainly stage I, grade II, estrogen receptor-positive, and HER2 negative. Metastatic diseases at diagnosis were higher in CIS-LIR group. A majority of patients received adjuvant systemic treatment, with no statistically significant differences between the 3 groups. There was no significant difference between the 3 groups in terms of OS or D-RFS.Conclusion: LIR after CIS does not appear to impact per se on survival of IBC.

Suggestions

Du même auteur

Monitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study

Archive ouverte | Chanteloup, Gaëtan | CCSD

International audience. Exosomes are nanovesicles released by all cells that can be found in the blood. A key point for their use as potential biomarkers in cancer is to differentiate tumour-derived exosomes from ot...

Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy

Archive ouverte | Roussot, Nicolas | CCSD

International audience

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Archive ouverte | Eliade, Marie | CCSD

IF 5.008 (2015/2016). International audience. Until recently, the molecular diagnosis of hereditary breast and ovarian cancer (HBOC) was mostly based on BRCA1/2 testing. Next generation sequencing and the recent dis...

Chargement des enrichissements...